Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ladrx Corporation is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. Prosecution is limited to 1 distinct examiner and 1 distinct art unit. This profile indicates that the company's immediate patent office activity is focused on a technical examination path. Such a centralized prosecution effort can be advantageous for maintaining consistency across the company's patent claims in the pharmaceutical field.
SCHLIENTZ, LEAH H is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This examiner manages the total volume of 1 pending office action for the applicant. Consequently, the prosecution strategy is centered on the feedback from this individual examiner and the standards of the 1 art unit involved. Practitioners should focus their efforts on addressing the specific concerns of SCHLIENTZ, LEAH H to move the application forward within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, LEAH H | 1 | 41.9% | +38.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17262133 | IMAGING AGENTS FOR RADIOLABELING EXOGENOUS AND ENDOGENOUS ALBUMIN | SCHLIENTZ, LEAH H | 35d overdue |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17262133 | IMAGING AGENTS FOR RADIOLABELING EXOGENOUS AND ENDOGENOUS ALBUMIN | SCHLIENTZ, LEAH H | 1618 | §103 | Final Rejection | 35d overdue | Pending | Jan 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial